Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research
Analysis of the Immunogenetic Profile of Patients With Aggressive Course of Malignant Neoplastic Process Resistant to the Standard Treatment Approaches: a Translational Study
N.N. Petrov National Medical Research Center of Oncology
1,000 participants
Sep 1, 1998
OBSERVATIONAL
Conditions
Summary
The investigators will collect biosamples of patient blood and tumour tissue for further immunological analysis of blood cell subpopulations, immunosupressive factors concentration, HLA expression an lymphocytes and tumour tissue, and and cancer testis antigenes expression on tumour cells, as well as clinical data on patient's stage, therapy, response and demographics. Possible prognostic and predictive dynamic biomarkers will be discovered for individualisation of treatment strategies
Eligibility
Inclusion Criteria5
- Signed inform consent
- Histolgically verified solid tumour
- Receiving systemic therapy for neoplasm
- Has archival tumour tissue
- Provide biosamples with living tumour tissue or blood samples for immunologic assessment
Exclusion Criteria6
- Concurrent Lymphoprolipherative disorder
- Patients after stem cell or bone marrow thansplantation
- Incomplete informaton on previous cancer history or medical history
- Patients with known primary immunodeficiency
- Patients receiving immunosupressive therapy for concurrent illness
- Pregnant patients
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05539677